TG Therapeutics
TGTX
352 hedge funds and large institutions have $3.07B invested in TG Therapeutics in 2025 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 130 increasing their positions, 111 reducing their positions, and 55 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 111
11% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 55
2.55% more ownership
Funds ownership: 62.41% → 64.96% (+2.5%)
1% less funds holding
Funds holding: 354 → 352 (-2)
14% less capital invested
Capital invested by funds: $3.58B → $3.07B (-$503M)
17% less call options, than puts
Call options by funds: $62M | Put options by funds: $74.9M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$62.8M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$20M |
| 3 |
BlackRock
New York
|
+$17.9M |
| 4 |
Goldman Sachs
New York
|
+$17.4M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$39.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$23M |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$21.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$13.5M |
TGTX Hedge Fund Activity: Q4 2025 in Review
352 of the 8,261 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2025, worth a combined $3.07B — down 14% from $3.58B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new TGTX positions and 55 closed out — a net gain of 6 holders — while 130 added to existing stakes and 111 trimmed.
The largest buyer was Congress Asset Management, opening a new position worth an estimated $62.8M. The largest seller was ClearBridge Investments, cutting an estimated $39.1M.
- 352 institutional investors held TG Therapeutics (TGTX) as of Q4 2025, down from 354 in Q3 2025.
- Funds reported $3.07B of TG Therapeutics stock for Q4 2025, down 14% quarter-over-quarter.
- 61 funds opened new TG Therapeutics positions in Q4 2025 and 55 closed out, a net change of +6 holders.
- The largest TG Therapeutics buyer in Q4 2025 was Congress Asset Management, an estimated $62.8M added.
- The largest TG Therapeutics seller in Q4 2025 was ClearBridge Investments, an estimated $39.1M sold.
Based on aggregated 13F filings for Q4 2025.